腹腔镜电透热与氦热凝固治疗轻中度子宫内膜异位症的随机对照试验
英国单中心平行组随机对照试验纳入192例16-50岁轻中度子宫内膜异位症女性,比较电透热与氦热凝固的腹腔镜治疗效果。意向性分析显示电透热组经期痛VAS在12周及所有时间点均显著低于氦组,性交痛在12周也显著改善,但效应量小于预设最小重要差异18.00 mm,临床意义有限。
要点
- 电透热在12周经期痛VAS较氦组低9.43 mm(95%CI 0.46-18.40,P=0.039),但小于18.00 mm最小重要差异。
- 电透热组性交痛12周VAS较氦组低11.66 mm(95%CI 1.39-21.93,P=0.026),同样未达临床重要阈值。
- 两组术中失血量无显著差异(氦组为参照的倍数变化1.43,95%CI 0.96-2.15,P=0.081)。
核心结论
- 电透热在统计上优于氦热凝固降低经期痛和性交痛,但效应量可能不足以达到临床显著。
研究设计与样本
- 英国子宫内膜异位症中心的平行组随机对照试验,纳入192例16-50岁非妊娠、临床诊断轻中度子宫内膜异位症女性。
- 腹腔镜确认轻中度子宫内膜异位症后随机分配至电透热或氦热凝固治疗,155例(81%)完成12周主要结局评估。
主要发现
- 意向性分析中,电透热组12周经期痛VAS评分显著低于氦组(均差9.43 mm,95%CI 0.46-18.40 mm,P=0.039)。
- 电透热组所有时间点经期痛VAS均显著低于氦组(均差10.13 mm,95%CI 3.48-16.78 mm,P=0.003)。
- 电透热组12周性交痛VAS显著低于氦组(均差11.66 mm,95%CI 1.39-21.93 mm,P=0.026),但效应小于预设最小重要差异18.00 mm。
- 部分生活质量维度差异 favoring 电透热,术中失血量两组无显著差异(氦组为参照的倍数变化1.43,95%CI 0.96-2.15,P=0.081)。
关键数值与推荐
- 主要结局为经期痛和性交痛,采用100 mm视觉模拟量表(VAS)评估,时间点为基线及术后6、12、36周。
- 预设最小重要差异为18.00 mm,电透热与氦组的VAS均差均未达到该阈值。
临床怎么用
- 电透热与氦热凝固均可用于腹腔镜治疗轻中度子宫内膜异位症,但电透热的疼痛改善幅度可能不具有临床意义。
- 选择能量方式时需结合操作者经验与设备可用性,不应仅依据统计学的微小差异。
局限性
- 单中心研究,外部推广性受限。
- 12周主要结局仅81%完成,存在失访偏倚可能。
- 疼痛改善效应量小于预设最小重要差异,临床意义有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare electrodiathermy with helium thermal coagulation in laparoscopic treatment of mild-to-moderate endometriosis. DESIGN: Parallel-group randomised controlled trial. SETTING: A UK endometriosis centre. POPULATION: Non-pregnant women aged 16-50 years with a clinical diagnosis of mild-to-moderate endometriosis. METHODS: If mild or moderate endometriosis was confirmed at laparoscopy, women were randomised to laparoscopic treatment with electrodiathermy or helium thermal coagulator. MAIN OUTCOME MEASURES: Cyclical pain and dyspareunia (rated on a 100-mm visual analogue scale, VAS), quality of life at baseline and at 6, 12 and 36 weeks following surgery, operative blood loss and surgical complications. RESULTS: A total of 192 women were randomised. Of these, 155 (81%) completed the primary outcome point at 12 weeks. In an intention-to-treat analysis, VAS scores for cyclical pain were significantly lower in the electrodiathermy group compared with the helium group at 12 weeks (mean difference, 9.43 mm; 95% CI 0.46, 18.40 mm; P = 0.039) and across all time points (mean difference, 10.13 mm; 95% CI 3.48, 16.78 mm; P = 0.003). A significant difference in dyspareunia also favoured electrodiathermy at 12 weeks (mean difference, 11.66 mm; 95% CI 1.39, 21.93 mm; P = 0.026). These effects were smaller than the proposed minimum important difference of 18.00 mm, however. Differences in some aspects of quality of life favoured electrodiathermy. There was no significant difference in operative blood loss (fold-change with helium as reference, 1.43; 95% CI 0.96, 2.15; P = 0.081). CONCLUSIONS: Although electrodiathermy was statistically superior to helium ablation in reducing cyclical pain and dyspareunia, these effects may be too small to be clinically significant. TWEETABLE ABSTRACT: Helium coagulation is not superior to electrodiathermy in laparoscopic treatment of mild-to-moderate endometriosis.
引用
- Misra G, Sim J, El-Gizawy Z, et al. Laparoscopic ablation or excision with helium thermal coagulator versus electrodiathermy for the treatment of mild-to-moderate endometriosis: randomised controlled trial. BJOG. 2020. PMID: 32340075. doi:10.1111/1471-0528.16279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。